Merck & Co have seen revenues drop by 4 per cent in their third quarter, as their diabetes blockbuster, Januvia, continued to show signs of weakness in the US. Sales were reported to be $11 billion, with Merck’s DPP-4 inhibitor Januvia (sitagliptin) down 5% to $927 million. Line extension Janumet (sitagliptin and metformin) fared slightly
Eli Lilly have revealed a positive set of financials for their third quarter of 2013, which was aided by cost-cutting and continued strong sales of Cymbalta. Net income dropped by 9% to $1.20 billion, although it is worth noting that Eli Lilly’s results from Q3 of 2012 included an early payment of $787 million from
The Clinical Professionals Group, which includes the team at Only Medics, raised over £200 for Breast Cancer Care on Friday 18th October, as part of Breast Cancer Awareness Month. The offices took part in a variety of ‘pink’ themed activities throughout the day, including a pink themed quiz and sponsored pink nail painting for some of
Roche have revealed positive financial results for the third quarter, strengthened by the sustained growth of their cancer drugs. Earlier today Roche announced that sales reached 11.57 billion Swiss francs, an increase of 8%, while their pharmaceutical revenue grew by 9% to 9.03 billion Swiss francs. Roche’s best-selling drug was MabThera/Rituxan (rituximab), which has been
Many NHS doctors who wish to move into the pharmaceutical industry do not have a good enough understanding of the skills needed in a corporate culture. This was one of the findings of a think tank hosted by the Only Medics team. As it currently stands, less than 10% of NHS budgets are spent on
Johnson & Johnson’s Janssen Pharmaceuticals has acquired an investigational antiviral from GlaxoSmithKline (GSK) with the aim to develop an oral regimen for the treatment of hepatitis C (HCV). The pharmaceutical company has paid to obtain access to the NS5a replication complex inhibitor GSK2336805, which GlaxoSmithKline and their partner, Vertex, had taken up to clinical Phase
Only Medics, part of the Clinical Professionals Group, held a Physicians to Pharma event last Thursday, aimed to help medics who are looking to transition into the pharmaceutical industry. The event was invite only, and was attended by a select number of medics, in addition to a range of industry professionals and members of the
After recently signing an anti-inflammatory deal with Ablynx, AbbVie has now announced a new agreement with Galapagos in cystic fibrosis. Specifically, the organisations have confirmed that they will contribute technologies and resources to develop oral drugs that address the main mutations in cystic fibrosis patients, including F508del and G551D, with the intention of starting Phase
Only Medics will be hosting a day of workshops for medics looking to transition to the pharmaceutical industry. The workshop will take place on Thursday 26th September in Reading, UK. Attendance to the workshop is by invitation only. In addition to medics, the workshop will be attended by industry physicians and HR professionals, some of whom are actively
AstraZeneca have announced that they have licensed a drug which is currently in mid-stage clinical studies for ovarian cancer from Merck & Co. The agreement revolves around MK-1775, an oral small molecule inhibitor of WEE1 kinase, a cell cycle checkpoint protein regulator. Preclinical results have indicated that disruption of WEE1 may improve the cell killing
